John Kemp


John was most recently CSO at Syndesi Therapeutics, which was acquired by Abbvie in March 2022 in a USD 1 B deal. He brings 30 years of experience in CNS drug discovery and development He previously held positions as Chief R&D Officer at Evotec, head of CNS research at Roche, and Senior Director, Neuroscience Discovery at Janssen. John has published over 140 peer-reviewed articles.